In conclusion, basal weekly long-acting insulin shows similar and better glycemic efficacy than daily basal insulin in T1DM and T2DM due to its association with less hypoglycemia, a reduction in the number of injections and its proven effectiveness. The gene discussed is INS; the disease is type 1 diabetes mellitus.